Skip to main content

Phase II evaluation of nintedanib in the treatment of bevacizumab-resistant persistent/recurrent ovarian, fallopian tube, or primary peritoneal carcinoma.

Publication ,  Conference
Davidson, BA; Squatrito, R; Duska, LR; Havrilesky, LJ; Schwager, N; McCollum, M; Arapovic, S; Secord, AA
Published in: Journal of Clinical Oncology
May 20, 2016

Duke Scholars

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2016

Volume

34

Issue

15_suppl

Start / End Page

TPS5601 / TPS5601

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Davidson, B. A., Squatrito, R., Duska, L. R., Havrilesky, L. J., Schwager, N., McCollum, M., … Secord, A. A. (2016). Phase II evaluation of nintedanib in the treatment of bevacizumab-resistant persistent/recurrent ovarian, fallopian tube, or primary peritoneal carcinoma. In Journal of Clinical Oncology (Vol. 34, pp. TPS5601–TPS5601). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2016.34.15_suppl.tps5601
Davidson, Brittany Anne, Robert Squatrito, Linda R. Duska, Laura Jean Havrilesky, Nyssa Schwager, Michael McCollum, Sanja Arapovic, and Angeles Alvarez Secord. “Phase II evaluation of nintedanib in the treatment of bevacizumab-resistant persistent/recurrent ovarian, fallopian tube, or primary peritoneal carcinoma.” In Journal of Clinical Oncology, 34:TPS5601–TPS5601. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.tps5601.
Davidson BA, Squatrito R, Duska LR, Havrilesky LJ, Schwager N, McCollum M, et al. Phase II evaluation of nintedanib in the treatment of bevacizumab-resistant persistent/recurrent ovarian, fallopian tube, or primary peritoneal carcinoma. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. TPS5601–TPS5601.
Davidson, Brittany Anne, et al. “Phase II evaluation of nintedanib in the treatment of bevacizumab-resistant persistent/recurrent ovarian, fallopian tube, or primary peritoneal carcinoma.Journal of Clinical Oncology, vol. 34, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2016, pp. TPS5601–TPS5601. Crossref, doi:10.1200/jco.2016.34.15_suppl.tps5601.
Davidson BA, Squatrito R, Duska LR, Havrilesky LJ, Schwager N, McCollum M, Arapovic S, Secord AA. Phase II evaluation of nintedanib in the treatment of bevacizumab-resistant persistent/recurrent ovarian, fallopian tube, or primary peritoneal carcinoma. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. TPS5601–TPS5601.

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2016

Volume

34

Issue

15_suppl

Start / End Page

TPS5601 / TPS5601

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences